Investigating the safety of a diabetes medication in kidney transplant recipients
An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)
This study is looking at whether empagliflozin, a diabetes medication, can help improve kidney and heart health in veterans who have had kidney transplants, while also keeping an eye on any side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Omaha VA Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11030215 on NIH RePORTER |
What this research studies
This research focuses on evaluating the safety and effectiveness of empagliflozin, a medication typically used for diabetes, in veterans who have received kidney transplants. The study aims to determine if this medication can improve kidney and heart health in these patients, who often face significant cardiovascular risks. By conducting a multicenter clinical trial, the researchers will monitor the effects of empagliflozin on graft function and overall patient outcomes, while also assessing any potential side effects. This investigation is particularly important as kidney transplant recipients have been excluded from previous studies on this medication.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans who have undergone kidney transplantation and have type 2 diabetes.
Not a fit: Patients who do not have diabetes or have not received a kidney transplant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart and kidney health for kidney transplant recipients with diabetes.
How similar studies have performed: While there has been limited research on the use of SGLT2 inhibitors in kidney transplant recipients, studies in chronic kidney disease patients have shown promising results.
Where this research is happening
Omaha, United States
- Omaha VA Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mannon, Roslyn B — Omaha VA Medical Center
- Study coordinator: Mannon, Roslyn B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.